Uterine artery embolization for the treatment of adenomyosis efficacy analysis
article
OA: closed
CC0
AI-generated summary
Transcatheter uterine artery embolization demonstrated a 100% procedural success rate and significant clinical efficacy in treating adenomyosis, offering a minimally invasive option that preserves reproductive potential with fewer complications.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Objective To evaluate the uterine artery embolization for the treatment of adenomyosis of the clinical effect.Methods January 2008-January 2010 with uterine artery embolization for treatment of 69 cases of patients with adenomyosis,with uterine artery embolization for treatment and observation of clinical efficacy.Results 69 patients with 138 uterine artery catheterization all goes well,the successful completion of surgery,the success rate of 100%.Clinical efficacy :69 cases of uterine adenomyosis after 45 cases of dysmenorrhea in patients with complete remission,21 patients with apparent ease,3 patients relapsed.Conclusion Transcatheter uterine artery embolization for the treatment of adenomyosis,the clinical effects of precise,with less trauma and faster recovery without the need for removal of the uterus,a reliable short-term effect,less complications and shorter hospitalization time,retaining the advantages of reproductive potential for the treatment of uterine adenomyosis provides a new minimally invasive method of treatment.
Key words:
Uterine artery embolization; Uterine adenomyosis; Clinical efficacy
My notes (saved in your browser only)
Condition tags
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0
· commercial use OK